TY - JOUR
T1 - Factors associated with neuropsychiatric involvement in Latin American patients with systemic lupus erythematosus
AU - On behalf of GLADEL
AU - Barile-Fabris, Leonor A.
AU - Fragoso-Loyo, Hilda
AU - Wojdyla, Daniel
AU - Quintana, Rosana
AU - Pons-Estel, Guillermo J.
AU - Catoggio, Luis J.
AU - García, Mercedes A.
AU - Saurit, Verónica
AU - Drenkard, Cristina
AU - Bonfa, Eloisa
AU - Borba, Eduardo F.
AU - Sato, Emilia
AU - Tavares Brenol, Joao C.
AU - Cavalcanti, Fernando
AU - Da Silva, Nilzio A.
AU - Lavras Costallat, Lilian T.
AU - Guibert Toledano, Marlene
AU - Massardo, Loreto
AU - Neira, Oscar
AU - Cardiel, Mario H.
AU - Amigo, Mary Carmen
AU - García De La Torre, Ignacio
AU - Silveira, Luis H.
AU - Acevedo Vásquez, Eduardo M.
AU - Chacón-Diaz, Rosa
AU - Esteva-Spinetti, María H.
AU - Alarcón, Graciela S.
AU - Pons-Estel, Bernardo A.
N1 - Publisher Copyright:
© The Author(s) 2021.
PY - 2021/8
Y1 - 2021/8
N2 - Introduction: Factors related to presentation of neuropsychiatric (NP) SLE manifestations, early in the course of the disease, and during follow up have not been clearly established. Purpose: To identify disease and non-disease related factors associated with NP manifestations in early SLE. Methods: We included 1193 patients from the GLADEL inception cohort free of NP involvement at cohort entry. We evaluated the association of demographic, clinical and laboratory data with NP involvement during follow-up. Statistical methods: Independent factors associated with NP involvement were identified using a multivariable Cox regression model. Results: Factors independently associated with NP manifestations were: mestizo ethnicity (HR 1.701, 95% CI 1.282–2.258, p = 0.0002), myalgias/myositis (HR 1.832, 95% CI 1.335–2.515, p = 0.0002), pneumonitis (HR 2.476, 95% CI 1.085–5.648, p = 0.0312), shrinking lung (HR 2.428, 95% CI 1.074–5.493, p = 0.0331) and hemolytic anemia (HR 1.629, 95% CI 1.130–2.347, p = 0.0089). Longer disease duration at cohort entry (13 to 24 months) was associated with a lower risk of developing NP manifestations (HR 0.642, 95% CI 0.441–0.934, p = 0.0206). Conclusions: Patients with myalgias/myositis, pneumonitis, shrinking lung and hemolytic anemia are at higher risk of NP involvement, whereas longer disease duration at cohort entry is associated with a lower risk of developing NP involvement.
AB - Introduction: Factors related to presentation of neuropsychiatric (NP) SLE manifestations, early in the course of the disease, and during follow up have not been clearly established. Purpose: To identify disease and non-disease related factors associated with NP manifestations in early SLE. Methods: We included 1193 patients from the GLADEL inception cohort free of NP involvement at cohort entry. We evaluated the association of demographic, clinical and laboratory data with NP involvement during follow-up. Statistical methods: Independent factors associated with NP involvement were identified using a multivariable Cox regression model. Results: Factors independently associated with NP manifestations were: mestizo ethnicity (HR 1.701, 95% CI 1.282–2.258, p = 0.0002), myalgias/myositis (HR 1.832, 95% CI 1.335–2.515, p = 0.0002), pneumonitis (HR 2.476, 95% CI 1.085–5.648, p = 0.0312), shrinking lung (HR 2.428, 95% CI 1.074–5.493, p = 0.0331) and hemolytic anemia (HR 1.629, 95% CI 1.130–2.347, p = 0.0089). Longer disease duration at cohort entry (13 to 24 months) was associated with a lower risk of developing NP manifestations (HR 0.642, 95% CI 0.441–0.934, p = 0.0206). Conclusions: Patients with myalgias/myositis, pneumonitis, shrinking lung and hemolytic anemia are at higher risk of NP involvement, whereas longer disease duration at cohort entry is associated with a lower risk of developing NP involvement.
KW - Systemic lupus erythematosus
KW - neuropsychiatric manifestations
KW - prognostic factors
UR - http://www.scopus.com/inward/record.url?scp=85107311120&partnerID=8YFLogxK
U2 - 10.1177/09612033211020364
DO - 10.1177/09612033211020364
M3 - Article
C2 - 34082589
AN - SCOPUS:85107311120
SN - 0961-2033
VL - 30
SP - 1481
EP - 1491
JO - Lupus
JF - Lupus
IS - 9
ER -